Richter-Helm bringing new opportunities to BIO-Europe Paris

Hamburg, Germany: Highly respected German contract manufacturer and developer Richter-Helm will be bringing a wide range of business opportunities to discuss at the forthcoming BIO-Europe Spring event in Paris.

Richter-Helm is a silver sponsor of the flagship three-day event, which opens on March 9 and will again be an exhibitor there.

In-licensing and out-licensing opportunities

The Richter-Helm team at Booth 46 at the Paris Expo Center will be holding details of a range of new opportunities that the company’s researchers and production experts have developed. These include new potential applications in microbial contract development and manufacturing and in-licensing options.

Richter-Helm is also seeking to identify potential new out-licensing partners for its range of biosimilars.

Networking and partnering

“We are delighted to be heading for BIO-Europe Spring in Paris,” said Richter-Helm’s Business Development Manager, Tamara Rupp.

“This event provides an excellent platform for us to get in touch with new associates via one-to-one meetings and meet long-standing business partners. “We’re particularly looking forward to meeting CEOs from pharma and biotech companies, heads of out-licensing, business development managers and people responsible for CMC, which are interested in our contract development and manufacturing services,” she added.

Richter-Helm will attendthe prescheduled one-to-one meetings organized through the partnering ONE system of the EBD group and is looking forward to welcome you at their booth.

About Richter-Helm

Richter-Helm is a German-based contract development and manufacturing organization (CDMO) that specializes in process development and GMP-compliant manufacture of products derived from microbial expression systems, principally bacteria and yeasts.

Richter-Helm is one of Europe’s longest established biotechnology companies, with more than 25 years of experience in the development and GMP production of recombinant proteins, plasmid DNA and microbial vaccines.

Richter-Helm offers services with highest pharmaceutical quality, confirmed by many audits of customers and regulatory authorities (FDA, EMA, ANVISA, MFDS). The services include process development and GMP manufacturing for preclinical and clinical trials as well as commercial supply and related fill and finish operations.

The company has developed its own products, including a highly promising drug now in late-stage clinical trials. It also provides an ideal platform for its owners, Gedeon Richter and Helm AG, to develop worldwide licensing options as well as partnerships for co-development and marketing of biopharmaceutical development projects.